Cyclacel Pharmaceuticals Reports Second Quarter 2019 Financial Results
Cyclacel Pharmaceuticals, Inc. (CYCC)
Last cyclacel pharmaceuticals, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.cyclacel.com/investor-relations
Company Research
Source: GlobeNewswire
- Conference Call Scheduled August 13, 2019 at 4:30 p.m. ET – BERKELEY HEIGHTS, N.J., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported financial results and business highlights for the second quarter 2019. The Company's net loss applicable to common shareholders for the three months ended June 30, 2019 was $1.8 million. As of June 30, 2019 cash and cash equivalents totaled $15.2 million. “We are excited to report new evidence of anticancer activity for CYC065. In part 2 of our Phase 1 study of CYC065 as a single agent, a patient with endometrial cancer with MCL1 amplification treated on the fourth dose level achieved tumor shrinkage. This patient was previously treated with liposomal doxorubicin, carboplatin, and multiple investigational therapies,” said Spiro Rombotis, President and Chief Executive O
Show less
Read more
Impact Snapshot
Event Time:
CYCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYCC alerts
High impacting Cyclacel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CYCC
News
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewswire
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
CYCC
Earnings
- 3/19/24 - Beat
CYCC
Sec Filings
- 3/28/24 - Form 8-K
- 3/25/24 - Form S-1
- 3/21/24 - Form 10-K
- CYCC's page on the SEC website